Minocycline in the treatment of acne: Latest findings

Giornale Italiano di Dermatologia e Venereologia

Volumn 145, Issue 3, 2010, Pages 425-429

  Maffeis, L ^a   Veraldi, S ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acne vulgaris; Minocycline; Propionibacterium acnes

Indexed keywords

BACTERIAL PROTEIN; BENZOYL PEROXIDE; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MINOCYCLINE; NEUTROPHIL COLLAGENASE;

ACNE; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; DIZZINESS; DRUG ABSORPTION; DRUG FORMULATION; GRAM NEGATIVE BACTERIUM; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PROPIONIBACTERIUM; PROTEIN SYNTHESIS; REVIEW; SERUM SICKNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 77956824007     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's The pharmacological basis of therapeutics, 11/E. New York: Mc-Graw-Hill; 2006.
2. Bernier C, Dréno B. Minocycline. Ann Dermatol Venereol 2001;128:627-37.
3. Garner SE, Eady A, Popescu CM, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003;1:CD002086.
4. Smith K, Leyden JJ. Safety of doxycicline and minocycline: a systematic review. Clin Ther 2005;27:1329-42.
5. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997;133:1224-30.
6. Bocker R, Estler CJ, Ludewig-Sanding D. Evaluation of the hepatotoxic potential of minocycline. Antimicrob Agents Chemother 1991;35:1434-6.
7. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996;134:693-5. (Pubitemid 26120737)
8. Cooper AJ. Sistematic review of Propionibacterium acnes resistance to systematic antibiotics. Med J Aust 1998;169:259-61.
9. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin 2007;25:127-32.
10. Sapadin AN, Fleischmaker R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65.
11. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin 2007;25:133-5.
12. Weinberg JM. The anti-inflammatory effect of tetracyclines. Cutis 2005;75(S4):6-11.
13. Celerier P, Litoux P, Dreno B. In vitro modulation of epidermal inflammatory cytokines (alpha, IL-6, TNF alpha) by minocycline. Arch Dermatol Res 1996;288:411-4.
14. Kloppenburg M, Verweij CL, Miltenburg AM, et al. The influence of tetracyclines on T cell activation. Clin Exp Immunol 1995;102:635-41.
15. Eady EA, Ingham E, Walters CE, Cove JH, Cunliffe WJ. Modulation of comedonal levels of interleukin-1 in acne patients treated with tetracyclines. J Invest Dermatol 1993;101:86-91. (Pubitemid 23213018)
16. Ochsendorf F. Systemic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges 2006;4:828-41.
17. Del Rosso JQ, Kim G. Optimizing use of oral antibiotics in acne vulgaris. Dermatol Clin 2009;27:33-42.
18. Stewart DM, Torok HM, Weiss JS, Plott RT; Solodyn Phase 2 Study Group. Dose-ranging efficacy of new once-daily extended-release minocycline for acne vulgaris. Cutis 2006;78(S4):11-20.
19. Leyden JJ. Extended-release minocycline-first systemic antibiotic approved for the treatment of acne: introduction. Cutis 2006;78(S4):4-5.
20. Plott RT, Wortzman. Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets. Cutis 2006;78:6-10.
21. Fleischer AB Jr, Dinehart S, Stough D, Plott RT; Solodyn Phase 2 Study Group; Solodyn Phase 3 Study Group. Safety and efficacy of a new extended-release formulation of minocycline. Cutis 2006;78(S4):21-31.
22. Del Rosso JQ. Clinical significance of brand versus generic formulations: focus on oral minocycline. Cutis 2006;77:153-6.
23. Donnet A, Dufour H, Graziani N, Grisoli F. Minocycline and benign intracranial hypertension. Biomed Pharmacother 1992;46:171-2.
24. Sainte-Marie I, Tenaud I, Jumbou O, Dréno B. Minocycline modulation of alpha-MSH production by keratinocytes in vitro. Acta Derm Venereol 1999;79:265-7. (Pubitemid 29302051)
25. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Arch Dermatol 1996;132:934-9.
26. Somech R, Arav-Boger R, Assia A, Spirer Z, Jurgenson U. Complications of minocycline therapy for acne vulgaris. Case reports and review of the literature. Pediatr Dermatol 1999;16:469-72.
27. Piette AM, Ramanoelina J, Gepner P. Systemic reaction induced by minocycline treatment: a report of four patients and review of the literature. Rev Med Interne 1999;20:869-74.
28. Thibault MJ, Billick RC, Srolovitz H. Minocycline-induced Sweet's syndrome. J Am Acad Dermatol 1992;27:801-4.
29. Okano M, Imai S. Anaphylactoid symptoms due to oral minocycline. Acta Derm Venereol (Stockh) 1996;76:164. (Pubitemid 26135382)
30. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ et al. Management of acne: report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003;49:S1-37. (Pubitemid 36791495)
31. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ et al. New insights into the management of acne: an update from the Global Alliance to improve outcomes in Acne Group. J Am Acad Dermatol 2009;60:S1-50.
32. Del Rosso JQ. Recently approved systemic therapies for Acne Vulgaris and Rosacea. Cutis 2007;80:113-20.
33. Leyden J, Kaidbey K, Levy S. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol 2001;2:263-6. (Pubitemid 32738668)
34. Lookingbill DP, Dhalker DK, Lindholm JS. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997;37:590-5.
35. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003;49:S206-210.
36. st Hawaii Dermatology Seminar. Wailea, Maui, Hawaii, March 3-9, 2007. (poster)